- Home
- GGAL vs ARWR Comparison
GGAL vs ARWR Comparison
Compare GGAL & ARWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GGAL | ARWR |
|---|---|---|
| Founded | 1905 | 2003 |
| Country | Argentina | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.7B | 9.6B |
| IPO Year | N/A | 1993 |
Fundamental Metrics
Financial Performance| Metric | GGAL | ARWR |
|---|---|---|
| Price | $56.04 | $63.61 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 10 |
| Target Price | ★ $67.50 | $63.70 |
| AVG Volume (30 Days) | 1.1M | ★ 2.2M |
| Earning Date | 03-07-2023 | 02-09-2026 |
| Dividend Yield | ★ 2.00% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.35 | N/A |
| Revenue | ★ $3,630,934,738.00 | $829,448,000.00 |
| Revenue This Year | $12.64 | N/A |
| Revenue Next Year | $18.04 | N/A |
| P/E Ratio | $16.82 | ★ N/A |
| Revenue Growth | N/A | ★ 23258.15 |
| 52 Week Low | $25.89 | $9.57 |
| 52 Week High | $74.00 | $72.36 |
Technical Indicators
Market Signals| Indicator | GGAL | ARWR |
|---|---|---|
| Relative Strength Index (RSI) | 63.78 | 50.93 |
| Support Level | $52.36 | $65.94 |
| Resistance Level | $56.28 | $69.71 |
| Average True Range (ATR) | 1.93 | 3.43 |
| MACD | 0.15 | -1.40 |
| Stochastic Oscillator | 96.93 | 32.66 |
Price Performance
Historical ComparisonAbout GGAL Grupo Financiero Galicia S.A.
Grupo Financiero Galicia SA is a financial service holding company. It provides general banking services, proprietary brand credit card services, personal loans, insurance, and other services. The company's operating business segments are Banks, Ecosistema Naranja X, Insurance, Adjustments, and Other Businesses. It generates maximum revenue from Banks. Geographically its operate in Argentina, Uruguay, and the majority of its revenue comes from Argentina.
About ARWR Arrowhead Pharmaceuticals Inc.
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.